Zynerba Pharmaceuticals

Zynerba Pharmaceuticals is a company based in Devon, Pennsylvania, with 18 employees. Zynerba Pharmaceuticals is dedicated to developing and commercializing next-generation cannabinoid therapeutics formulated for transdermal delivery. They focus on treating rare and near-rare neuropsychiatric disorders where there is a high unmet medical need. Their lead product candidate, Zygel™, is a pharmaceutically-produced cannabidiol gel designed for transdermal delivery. Zygel is currently in clinical development for Fragile X Syndrome, 22q11.2 Deletion Syndrome, and Autism Spectrum Disorder. Zynerba differentiates itself through its use of transdermal delivery, which they believe can reduce adverse effects associated with oral dosing. This method allows for direct absorption of the drug through the skin, bypassing the gastrointestinal tract and potentially enabling lower dosage levels. For more information about Zynerba Pharmaceuticals, visit their website at zynerba.com.